AstraZeneca's Motavizumab May Be The Canary In The Follow-On Coal Mine
When a significant drug application hits a snag, it can sometimes feel like the whole industry stumbles. Such is the case with AstraZeneca PLC’s motavizumab, which protects against the effects of respiratory syncytial virus and recently failed to get a timely regulatory approval. This suggests the government agency’s standards may be changing on a range of issues, from comparative effectiveness to data integrity.
You may also be interested in...
If MedImmune wants to move forward with Rezield (motavizumab), its preventive treatment for respiratory syncytial virus disease, it will likely have to demonstrate some advantage over its currently approved product, Synagis (palivizumab)
As the health care reform debate focuses on the appropriate role of comparative effectiveness research, a look at FDA’s review practices gives some insight into how the agency already takes the concept into account in its review decisions.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.